Ursosan in the complex treatment of patients with non-alcoholic fatty liver disease and its role in the correction of metabolic disorders (Svet study)
- 作者: Cheremukhina Y.V.1,2, Borovkova N.Y.2, Ermilova O.A.1, Tokareva A.S.2, Kuznetsov A.N.2, Vasilkova A.S.2
-
隶属关系:
- N A. Semashko Nizhny Novgorod Regional Clinical Hospital
- Privolzhsky Research Medical University of the Ministry of Healthcare of Russia
- 期: 卷 11, 编号 8 (2025)
- 页面: 165-173
- 栏目: ACTUAL ISSUES OF PHARMACOTHERAPY AND PREVENTIVE TREATMENT
- URL: https://journals.eco-vector.com/2412-4036/article/view/696098
- DOI: https://doi.org/10.18565/therapy.2025.8.165-173
- ID: 696098
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Non-alcoholic fatty liver disease (NAFLD) is an actual problem for medical community due to its high prevalence, association with other metabolically associated diseases, and asymptomatic early stages, which can contribute to the subsequent development of serious complications. To date, the choice of effective hepatoprotective therapy for NAFLD remains to be an open question.
The aim: to evaluate the efficacy of Ursosan (ursodeoxycholic acid) and its role in correcting metabolic disorders as a part of the comprehensive treatment of NAFLD patients.
Material and methods. We analyzed the treatment of 53 patients with NAFLD, who were focusing on a low-calorie diet and balanced physical activity. They were randomized by gender and age and divided into two groups based on the treatment regimen. Subjects in Group 1, in addition to non-pharmacological treatment methods, received Ursosan at a dose of 12 mg/kg/day for 6 months. Group 2 (the comparison group) consisted of patients who received only non-medicamentous treatment. All the participants were assessed dynamically (at baseline and after 6 months of treatment) for biochemical parameters of lipid, carbohydrate, and purine metabolism, as well as liver fat fraction (%), according to the data of abdominal magnetic resonance imaging.
Results. Patients with NAFLD, who received Ursosan as a part of combination therapy, had a significant improvement in lipid, carbohydrate, and purine metabolism. Total cholesterol levels after a 6-month course of the therapy decreased from 6.6 to 5.3 mmol/L (p = 0.001), triglycerides – from 1.9 to 1.6 mmol/L (p = 0.01), glucose – from 5.5 to 5.0 mmol/L (p = 0.06), uric acid – from 386 to 334 mmol/L (p = 0.001). Participants in Group 1 also showed a significant decrease in liver fat fraction relatively to the baseline level – from 12.25 to 6.0% (p = 0.002).
Conclusion. SVET study demonstrated that using Ursosan in the treatment of NAFLD not only reduces fatty liver damage but also improves metabolic profile of the patients.
全文:
作者简介
Yulia Cheremukhina
N A. Semashko Nizhny Novgorod Regional Clinical Hospital; Privolzhsky Research Medical University of the Ministry of Healthcare of Russia
编辑信件的主要联系方式.
Email: doctor.cheremuhina@gmail.com
ORCID iD: 0009-0001-4089-7583
MD, gastroenterologist at the Department of gastroenterology, assistant at the Department of internal medicine and general medical practice
俄罗斯联邦, Nizhny Novgorod; Nizhny NovgorodNatalya Borovkova
Privolzhsky Research Medical University of the Ministry of Healthcare of Russia
Email: borovkov-nn@mail.ru
ORCID iD: 0000-0001-7581-4138
MD, Dr. Sci. (Medicine), professor, first deputy director of the Institute of therapy, head of the Department of internal medicine and general medical practice
俄罗斯联邦, Nizhny NovgorodOlga Ermilova
N A. Semashko Nizhny Novgorod Regional Clinical Hospital
Email: doctor.cheremuhina@gmail.com
MD, PhD (Medicine), deputy chief physician for medical affairs
俄罗斯联邦, Nizhny NovgorodAnastasia Tokareva
Privolzhsky Research Medical University of the Ministry of Healthcare of Russia
Email: tokareva_a@pimunn.net
ORCID iD: 0000-0003-0640-6848
MD, assistant at the Department of internal medicine and general medical practice
俄罗斯联邦, Nizhny NovgorodAlexey Kuznetsov
Privolzhsky Research Medical University of the Ministry of Healthcare of Russia
Email: doctor.cheremuhina@gmail.com
ORCID iD: 0000-0003-1889-1297
MD, researcher of the department of functional diagnostics of University clinic, head of the Laboratory of immersive technologies and remote rehabilitation of the Department of information technologies
俄罗斯联邦, Nizhny NovgorodAnastasia Vasilkova
Privolzhsky Research Medical University of the Ministry of Healthcare of Russia
Email: doctor.cheremuhina@gmail.com
ORCID iD: 0000-0003-3826-3415
MD, PhD (Medicine), associate professor of the Department of internal medicine and general medical practice
俄罗斯联邦, Nizhny Novgorod参考
- Клинические рекомендации. Неалкогольная жировая болезнь печени. Российская ассоциация эндокринологов, Российская гастроэнтерологическая ассоциация, общероссийская общественная организация «Российское научное медицинское общество терапевтов», общероссийская общественная организация «Российская ассоциация геронтологов и гериатров», Российское общество по изучению печени, Российское общество профилактики неинфекционных заболеваний, Национальное общество профилактической кардиологии. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 748_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/748_2 (дата обращения – 17.10.2025). [Clinical guidelines. Non-alcoholic fatty liver disease. Russian Association of Endocrinologists, Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Association of Gerontologists and Geriatricians, Russian Society for the Study of the Liver, Russian Society for the Prevention of Non-Communicable Diseases, National Society of Preventive Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 748_2. URL: https://cr.minzdrav.gov.ru/view-cr/748_2 (date of access – 17.10.2025) (In Russ.)].
- Godoy-Matos AF, Silva Junior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60. PMID: 32684985. PMCID: PMC7359287. https://doi.org/10.1186/s13098-020-00570-y
- Селиверстов П.В., Джадхав С.Н., Цурцумия Д.Б., Ситкин С.И., Радченко В.Г. Неалкогольная жировая болезнь печени: возможности диагностики. РМЖ. 2019;27(5):36–40. [Seliverstov PV, Dzhadkhav SN, Tsurtsumia DB, Sitkin SI, Radchenko VG. Non-alcoholic fatty liver disease: Diagnostic possibilities. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2019;27(5):36–40 (In Russ.)]. EDN: NVDGKW.
- Маевская М.В., Котовская Ю.В., Ивашкин В.Т., Ткачева О.Н., Трошина Е.А., Шестакова М.В. с соавт. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216–253. [Maevskaya MV, Kotovskaya YuV, Ivashkin VT, Tkacheva ON, Troshina EA, Shestakova MV et al. National consensus for physicians on the management of adult patients with non-alcoholic fatty liver disease and its main comorbid conditions. Terapevticheskiy arkhiv = Therapeutic Archive. 2022;94(2):216–253 (In Russ.)]. EDN: CODINB. https://doi.org/10.26442/00403660.2022.02.201363
- Ma W, Wu W, Wen W, Xu F, Han D, Lyu J, Huang Y. Association of NAFLD with cardiovascular disease and all-cause mortality: A large-scale prospective cohort study based on UK Biobank. Ther Adv Chronic Dis. 2022;13:20406223221122478. PMID: 36159632. PMCID: PMC9493675. https://doi.org/10.1177/20406223221122478
- Шавкута Г.В., Туркина C.В. НАЖБП – предиктор высокого риска развития и ко-фактор прогрессирования сердечно-сосудистых заболеваний. Южно-Российский журнал терапевтической практики. 2024;5(2):29–37. [Shavkuta GV, Turkina SV. NASH is a predictor of a high risk of developing and a co-factor of the progression of cardiovascular diseases. Yuzhno-Rossiyskiy zhurnal terapevticheskoy praktiki = South Russian Journal of Therapeutic Practice. 2024;5(2):29–37 (In Russ.)]. EDN: WMRWMN. https://doi.org/10.21886/2712-8156-2024-5-2-29-37
- Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. J Hepatol. 2023;77(4):1335–47. PMID: 36626630. PMCID: PMC10026948. https://doi.org/10.1097/HEP.0000000000000004
- Драпкина О.М., Евстифеева С.Е., Шальнова С.А., Куценко В.А., Баланова Ю.А., Имаева А.Э. с соавт. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025;24(2):6–16. [Drapkina OM, Evstifeeva SE, Shalnova SA, Kutsenko VA, Balanova YuA, Imaeva AE et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(2):6–16 (In Russ.)]. EDN CVQNXA. https://doi.org/10.15829/1728-8800-2025-4316
- Кролевец Т.С., Ливзан М.А. Неалкогольная жировая болезнь печени: дайджест 2021. Доказательная гастроэнтерология. 2021;10(2):27–35. [Krolevets TS, Livzan MA. Non-alcoholic fatty liver disease: Digest 2021. Dokazatel’naya gastroenterologiya = Russian Journal of Evidence-Based Gastroenterology. 2021;10(2):27–35 (In Russ.)]. EDN: UKXSIH. https://doi.org/10.17116/dokgastro20211002127
- Маевская М.В., Надинская М.Ю., Луньков В.Д., Пирогова И.Ю., Чесноков Е.В., Кодзоева Х.Б., Ивашкин В.Т. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):22–29. [Mayevskaya MV, Nadinskaia MYu, Lunkov VD, Pirogova IYu, Chesnokov EV, Kodzoeva KhB, Ivashkin VT. An effect of ursodeoxycholic acid on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease: Results of the USPEH study. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, and Proctology. 2019;29(6):22–29 (In Russ.)]. EDN: AJZEKK. https://doi.org/10.22416/1382-4376-2019-29-6-22-29
- Пирогова И.Ю., Яковлева С.В., Неуймина Т.В., Синицын С.П., Чулков В.С. Влияние препарата УрСосан на стеатоз и Фиброз печени, а также показатЕли метаболического синдРома у больных с неалкогольной жировой болезнью печени: сравнительное исследование «СФЕРА». Гастроэнтерология. Приложение к журналу Consilium Medicum. 2018;(1):7–14. [Pirogova IYu, Yakovleva SV, Neujmina TV, Sinitsyn SP, Chulkov VS. The effect of UrSosan on liver steatosis and fibrosis, as well as indicators of metabolic syndrome in patients with non-alcoholic fatty liver disease: a comparative study by SPHERE. Gastroenterologiya. Prilozheniye k zhurnalu Consilium Medicum = Gastroenterology. Supplement to the journal Consilium Medicum. 2018;(1):7–14 (In Russ.)]. EDN: XQBWBF. https://doi.org/10.26442/2414-3529_2018.1.7-14
- Маевская М.В. Урсодезоксихолевая кислота: уникальные свойства и клиническое применение. Медицинский совет. 2023;17(8):96–105. [Maevskaya MV. Ursodeoxycholic acid: Unique properties and clinical application. Meditsinskiy sovet = Medical Council. 2023;17(8):96–105 (In Russ.)]. EDN: KHJXSW. https://doi.org/10.21518/ms2023-136
- Дуданова О.П., Шиповская А.А., Ларина Н.А., Курбатова И.В., Радченко В.Г., Селиверстов П.В. Гепатотропные и метаболические свойства урсодезоксихолевой кислоты при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2024;(4):4–9. [Dudanova OP, Shipovskaya AA, Larina NA, Kurbatova IV, Radchenko VG, Seliverstov PV. Hepatotropic and metabolic properties of ursodeoxycholic acid in non-alcoholic fatty liver disease. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2024;(4):4–9 (In Russ.)]. EDN: NYFSXE. https://doi.org/10.31146/1682-8658-ecg-224-4-4-9
补充文件
